# A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

> **NCT04548843** · PHASE1 · WITHDRAWN · sponsor: **Minovia Therapeutics Ltd.**

## Conditions studied

- Primary Mitochondrial Diseases

## Interventions

- **PROCEDURE:** Bone Marrow mobilization
- **PROCEDURE:** Apheresis
- **BIOLOGICAL:** MNV-BM-PLC infusion

## Key facts

- **NCT ID:** NCT04548843
- **Lead sponsor:** Minovia Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548843, "A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04548843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*